Results 141 to 150 of about 65,642 (180)

TMEM121 suppresses cervical cancer cell proliferation and migration via interaction with the ERK pathway. [PDF]

Am J Cancer Res
Wang H, Xu S, Li S, Lin M, Jiao Z, Zhao J, Wu D, Huang Y, Liu S, Ge S, Wu X, Li F, Guo L, Fan X.   +13 more
europepmc   +1 more source

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. [PDF]

Cells
Garg V, Hofmann RNHM, Saleem M, Mirzaiebadizi A, Hashemi GS, Hameed T, Jooyeh B, Pudewell S, Mehrabipour M, Mosaddeghzadeh N, Piekorz RP, Ahmadian MR.   +11 more
europepmc   +1 more source

Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy. [PDF]

Front Immunol
Ma J, Zhang D, Cui Y, Meng D, Wei Z, Ye X.   +5 more
europepmc   +1 more source

3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth. [PDF]

PLoS One
Nam AY, Joo SH, Lee NY, Yoon G, Park JW, Na M, Shim JH.   +6 more
europepmc   +1 more source

EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy. [PDF]

Cancer Sci
Gao J, Jiao X, Ren F, Wu X, Tan J, Bai Y, Dai Y, Shen L, Wu C, Shen L.   +9 more
europepmc   +1 more source

PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma. [PDF]

Cell Oncol (Dordr)
Qian R, Guo Y, Hu X, Ling J, Geng H, Ye Q, Zhang L, Zhan S, Liao L, Ge Y, Zheng Q, Cao Y.   +11 more
europepmc   +1 more source

Molecular Alterations and Pathways in Intrahepatic Cholangiocarcinoma: Available Evidence and New Perspectives. [PDF]

Int J Mol Sci
Astore M, Fabbri L, Monte A, Deiana C, Rizzo A, Tavolari S, Deserti M, Brandi G, Palloni A, Frega G.   +9 more
europepmc   +1 more source

Pharmacovigilance analysis of vision disorders relating to brimonidine treatment and mechanism study using network toxicology and molecular docking. [PDF]

Sci Rep
Xu L, Zhao S, Zhao S, Wang Z, Fang J, Cai C, Wang J.   +6 more
europepmc   +1 more source

Overexpressed MET drives aggressive thyroid cancer phenotypes and serves as a precision therapeutic target. [PDF]

Sci Rep
Xu R, Wan Y, Ding B.
europepmc   +1 more source